IFW

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

muary 28, 2005

Miyabi Grace

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/763,450

Group Art Unit:

1646

Applicant(s):

Mary Mah Lee Ng; Justin Jang Hann Chu Examiner:

To be assigned

Filing Date:

January 22, 2004

Docket No.

59419-010101

Title: MOLECULES, COMPOSITIONS,

Customer No.

33717

METHODS AND KITS FOR APPLICATIONS

ASSOCIATED WITH FLAVIVIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT [37 C.F.R. § 1.56]

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

This Information Disclosure Statement is being submitted within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office action on the merits, and therefore, Applicant believes no fee is required;

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is believed due with the submission of this paper. However, if the Applicants are mistaken, the Director is authorized to charge any required fee(s) or any underpayment of fee(s), or to credit any overpayments to Deposit Account Number 50-2638, Deposit Account Name Greenberg Traurig, LLP. Please ensure that the Attorney Docket Number is referred to when charging any payments or credits for this case.

Respectfully submitted,

GREENBERG TRAURIG, LL

Date January 28, 2005

Claude Nassif, Ph.D.

Reg. No. 52,061 Tel.: (310) 586-7828

Greenberg Traurig, LLP 2450 Colorado Avenue, Suite 400 Santa Monica, California 90404 Telephone: 310-586-7700

Facsimile: 310-586-7800

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Order the Faperwork Reduction Act of 1995, no persons are requir	ed to respond to a collection of informati	on unless it contains a valid OMB control number.
Substitute for form 1449/PTO	Co	mplete if Known
NIFORMATION DISCLOSURE	Application Number	10/763,450
STATEMENT BY APPLICANT	Filing Date	January 22, 2004
5 BIATEMENT BY APPLICANT	First Named Inventor	Mary NG Mah Lee
(use as many sheets as necessary)	Art Unit	1646
,6/	Examiner Name	To be assigned
1 of 4	Attorney Docket Number	59419-010101

Examiner Cite Document Number		Publication Date	DOCUMENTS Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where	
Initials*	Cite No. 1	Number-Kind Code 2 (if known)	MM-DD-YYYY	Document	Relevant Passages or Relevant Figures Appear
		US 4,376,110	03-08-1983	David et al.	

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,				
Initials*	No.1	Country Code ³ –Number ⁴ –Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear				

	99v01\59419.010101		
Examiner		Date .	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/763,450 Application Number INFORMATION DISCLOSURE Filing Date January 22, 2004 STATEMENT BY APPLICANT First Named Inventor Mary NG Mah Lee (use as many sheets as necessary) Art Unit 1646 **Examiner Name** To be assigned 2 4 59419-010101 Sheet of Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Adlish et al.; Identification of a putative cell receptor for human cytomegalovirus; Virology; 1990; Vol. 176; pp. 337-345.	
		Agnello et al.; Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor, Proc Natl Acad Sci; Oct 26, 1996; Vol. 96, No. 22; pp. 12766-12771.	
		Atkinson et al.; Purification and properties of HeLa cell plasma membranes; J Biol Chem; August 25, 1971; Vol. 246, No. 16; pp. 5162-5175.	
		Beasley et al.; Identification of neutralizing epitopes within structural domain III of the West Nile virus envelop protein; J. Virol.; Dec 2002; Vol. 76, No. 24, pp. 13097-13100.	
		Bielefeldt-Ohmann et al.; Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains; Virus Res.; 2001; Vol. 73; pp. 81-89.	
		Blau et al.; Entry and release of measles virus are polarized in epithelial cells; Virology; 1995; Vol. 210; pp. 91-99.	
		Borrow et al.; Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus; J Virol.; Dec 1992; Vol. 66, No. 12; pp. 7270-7281.	
		Bruett et al.; Characterization of a membrane-associated protein implicated in visna virus binding and infection; Virology; 2000; Vol. 271; pp. 132-141.	
		Cao et al.; Identification of α -Dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus; Science; Dec 11, 1998; Vol. 282; pp. 2079-2081.	
		Castle et al.; Primary structure of the West Nile flavivirus genome region coding for all nonstructural proteins. Virology; 1986; Vol. 149; pp. 10-26.	
		Castle et al.; Sequence analysis of the viral core protein and the membrane-associated proteins VI and NV2 of the flavivirus West Nile virus and of the genome sequence for these proteins; Virology; 1985; Vol. 145; pp. 227-236.	
		Chen et al.; Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate; Nat Med; Aug. 1997; Vol. 139, No. 8; pp. 239-251.	

_LA-FS1\314599v01\59419.010101	
Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Substitute for form 1449/PT	0		Co	mplete if Known
	INFORMATIO	N DI	SCLOSURE	Application Number	10/763,450
				Filing Date	January 22, 2004
STATEMENT BY APPLICANT				First Named Inventor	Mary NG Mah Lee
	(use as many s	sneets a	s necessary)	Art Unit	1646
				Examiner Name	To be assigned
Sheet	3	of	4	Attorney Docket Number	59419-010101

	NON PATENT LITERATURE DOCUMENTS
	Choi et al.; Reovirus binds to multiple plasma membrane proteins of mouse L
	fibroblasts; Virology; 1990; Vol. 178; pp. 316-320.
	Chu et al.; Infection of polarized epithelial cells with flavivirus West Nile: Polarized
	entry and egress of virus occur through apical surface; J Gen Virol.; 2002; Vol. 83;
	pp. 2427-2435.
	Chu et al.; Trafficking mechanism of West Nile (Sarafend) virus structural proteins; J
	Med Virol.; 2002; Vol. 67; pp. 127-1 36.
	Cote et al.; Generation of human monoclonal antibodies reactive with cellular antigens;
	Proc. Natl. Acad. Sci. USA; April 1983; Vol. 80; pp. 2026-2030.
	Crane et al.; Identification of cell membrane proteins that bind visna virus; J Virol.; Nov
	1991; Vol. 65, No. 11; pp. 6137-6143.
	Crill et al.; Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein
	are the most efficient blockers of virus adsorption to Vero cells; J Virol.; Aug 2001;
	Vol. 75, No. 16; pp. 7769-7773.
	Hasegawa et al.; Mutations in the envelope protein of Japanese encephalitis virus
	affect entry into cultured cells and virulence in mice; Virology; 1992; Vol. 191; pp. 158-
	165.
	Helenius; Alphavirus and flavivirus glycoproteins: structures and functions; Cell; June
	2, 1995; Vol. 81, pp. 651-653.
1	Kimura et al.; Analysis of virus-cell binding characteristics on the determination of
	Japanese encephalitis virus susceptibility; Arch Virol; 1994, Vol. 139; pp. 239-251.
1	Lee et al.; Substitutions at the Putative Receptor-Binding Site of an Encephalitic
	Flavivirus Alter Virulence and Host Cell Tropism and Reveal for Glycosaminoglycans in
	Entry; J. of Virology; Oct. 2000; Vol. 74, No. 19; pp. 8867-8875.
i	Martínez-Barragán et al.; Identification of a putative coreceptor on Vero cells that
1	participates in dengue 4 virus infection; J Virol.; Sep 2001; Vol. 75, No. 17; pp. 7818-
	7827.
	Ng et al.; Possible involvement of receptors in the entry of Kunjin virus into Vero cells;
	Arch Virol.; 1988; Vol. 100; pp. 199-211.
	Ng et al.; Transport and budding at two distinct sites of visible nucleocpasids of West
	Nile (Sarafend) virus; J Med Virol.; 2001; Vol. 65; pp. 758-764.

_LA-FS1\314599v01\59419.010101	
Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/763.450 Application Number INFORMATION DISCLOSURE Filing Date January 22, 2004 STATEMENT BY APPLICANT First Named Inventor Mary NG Mah Lee (use as many sheets as necessary) Art Unit 1646 **Examiner Name** To be assigned 4 4 Sheet of Attorney Docket Number 59419-010101

NON PATENT LITERATURE DOCUMENTS	
Putnak <i>et al.</i> ; A putative cellular receptor for dengue viruses; Nat Med.; Aug 1997; Vol. 3, No. 8; pp. 828-829.	
Rappole et al.; Migratory birds and spread of West Nile virus in the Western Hemisphere; Emerg Infect Dis; July-Aug 2000; Vol. 6, No. 4; pp. 319-328.	
Sagara <i>et al.</i> ; 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human Tcell lymphotropic virus type 1; J Virol; Jan 1998; Vol. 72, No. 1; pp. 535-541.	
Salas-Benito <i>et al.</i> ; Identification of two surface proteins from C6/36 cells that bind dengue type 4 virus; J Virol; Oct 1997; Vol. 71, No. 10; pp. 7246-7252.	
Schneider-Schaulies; Cellular receptors for viruses: links to tropism and pathogenesis; J Gen Virol.; 2000; Vol. 81, pp. 1413-1429.	
Se-Thoe <i>et al.</i> ; Alteration of virus entry mode: a neutralization mechanism for Dengue-2 virus; J Med Virol; 2000; Vol. 62, pp. 364-376.	
Taylor et al.; The human cytomegalovirus receptor on fibroblasts is a 30-kilodalton membrane protein; J Virol; June 1990; Vol. 64, No. 6; pp. 2484-2490.	
Thullier <i>et al.</i> ; Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism; J Gen Virol; 2001; Vol. 82, pp. 1885-1892.	-
Verdin <i>et al.</i> ; Characterization of a common high-affinity receptor for reovirus serotypes I and 3 on endothelial cells; J Virol; Mar 1989; Vol. 63, No. 3; pp. 1318-1 325.	

_LA-FS1\314599v01\59419.010101	
Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.